Evolution of thrombolytic therapy in patients with HeartWare ventricular assist device thrombosis: a single-institutional experience

Open in a separate window OBJECTIVESPump thrombosis remains a major challenge in heart failure patients with left ventricular HeartWare assist device. Current International Society for Heart and Lung Transplantation recommendations favour surgical pump exchange over lysis because safety and efficacy of lysis has been controversially reported. This study summarizes our experience on our HeartWare thrombosis prevention strategy as well as thrombolysis through implementation of our institutional standardized HeartWare assist device protocol.METHODSOutcomes of all HeartWare thrombosis patients admitted between 2010 and 2020 were analysed. Thrombolysis therapy using tissue plasminogen activator was used as the first-line therapy in this study and thrombolysis therapy efficacy was defined as freedom from stroke, bleeding, recurrent HeartWare assist device thrombosis or surgical device exchange within 30 days after lysis application.RESULTSA total of 507 patients have been included in this study and 66 patients (13%) collectively developed a first HeartWare-thrombosis after a median of 12 months (8–22 months) after HeartWare implantation. Forty patients were treated with unstandardized lysis, of whom 7 patients had thrombolysis associated complications, such as incomplete thrombus resolution requiring surgical pump exchange in 4 patients, but also intracranial haemorrhage occurring in 3 patients. Three patients died in the non-protocol group. Eight device thrombosis patients were treated according to our protocol, showing no lysis-associated complication.CONCLUSIONSDespite current recommendations, preferring surgical HeartWare pump exchange in thrombosis, thrombolysis therapy for first HeartWare thrombosis can be safe and effective in a standardized protocol setting, including anticoagulation adjustment and intensified blood pressure control management.     

癫痫病人MRI海马结构体积测定

目的测量正常成人及癫痫病人海马结构（ＨＦ）体积，探讨其在颞叶癫痫（ＴＬＥ）致痫灶定侧中的价值。材料与方法本组包括５２例正常成人及８９例癫痫病人，把病人分为三组：继发性癫痫４８例、特发颞叶外癫痫１５例、ＴＬＥ２６例，后者有２２例为顽固性癫痫。均作垂直于海马长轴的冠状位自旋回波（ＳＥ）序列Ｔ１加权像、ＴｕｒｂｏＳＥＴ２加权像，测量颞叶、ＨＦ体积和颞角、环池宽度，肉眼观察Ｔ２加权像海马信号强度改变。采用ＨＦ体积绝对值对ＴＬＥ定侧。结果获取了正常成人ＨＦ体积。２２例ＴＬＥＨＦ体积缩小，其中３例为双侧性；６例ＨＦ硬化经手术、病理证实，１例体积正常且致痫灶位于ＨＦ周围者ＨＦ硬化轻，８例其他类型癫痫病人ＨＦ体积略小，ＴＬＥ致痫灶定侧的敏感性为８５％，特异性为８７％。３例ＴＬＥ病人同侧前颞叶萎缩；部分ＴＬＥ病侧颞角、环池宽度增加；萎缩明显的ＨＦＴ２加权像信号弥漫性增高。结论ＨＦ体积缩小、Ｔ２加权像信号弥漫性增高是ＨＦ硬化萎缩的直接征象，与病变严重程度、致痫灶在颞叶的部位有关，前颞叶萎缩和颞角、环池增宽是ＨＦ硬化的辅助征象。ＨＦ萎缩不仅是颞叶癫痫的主要原因，也可能是其他类型癫痫发作的结果     

国家网络直报系统属地化数据交换与共享的设计与实现

为充分利用中国疾病预防控制中心建设的网络直报信息系统资源,避免重复建设,利用现有成熟的数据库数据交换和数据复制的解决方案,并辅助开发实现系统功能,国家与地方之间遵循统一规范的数据交换标准,建立数据交换接口,实现了属地化数据交换与共享。     

医学影像交班系统应用效果分析

设计开发骨科适用的医学影像交班系统,采用调查问卷方式比较影像交班和传统手工书写交班方式,评估系统应用效果,结果表明该系统能够提高专科信息化管理水平。     

Developing the Foundation for Syndromic Surveillance and Health Information Exchange for Yolo County,California

This report delineates Yolo County Health Department’s process to ascertain its optimal methods of participation in syndromic surveillance and health information exchange. As a health department serving a county of just 200,000 residents, Yolo County Health Department needed to operate within strict financial constraints. Meaningful Use legislation enabled it to pursue both syndromic surveillance and health information exchange participation whilst complying with its budgetary restrictions. The Health Information Technology for Economic and Clinical Health (HITECH), a segment of the American Recovery and Reinvestment Act of 2009, has incentivized the ‘Meaningful Use’ of electronic health records (EHRs) by providing incentive reimbursements and non-compliance penalties. The Meaningful Use of EHRs is to take place over 3 Stages: Stage 1 has begun, Stage 2 is imminent, and Stage 3 is currently being discussed.Having been solicited by both health information exchange and syndromic surveillance options which were cost-prohibitive, Yolo County Health Department focused attention on BioSense 2.0, a Meaningul Use-ready and virtually free syndromic surveillance program developed by the Federal Centers for Disease Control and Prevention. In collaboration with Sacramento County Department of Health and Human Services, and with support from several other area counties, Yolo County Health Department submitted a Funding Opportunity application for BioSense 2.0 regional implementation. Through this collaboration, Yolo County Health Department has begun participating in the formative stages of the Sacramento Area Center for Advanced Biosurveillance (SAC-B). Via SAC-B, Yolo County Health Department will be able to participate in syndromic surveillance in the BioSense 2.0 program, and simultaneously expand its electronic health data sharing towards a more comprehensive health information exchange.Lastly, over the course of these projects, three other methods of participating in electronic health data sharing became available to Yolo County Health Department: all three methods were the direct result of Meaningful Use legislation.     

血浆置换联合化疗对噬血细胞综合征疗效观察

目的:评价血浆置换联合化疗与单纯化疗对噬血细胞综合征的临床疗效。方法:采用回顾性研究,选取2008-02～2010-03在我院确诊并治疗的21例噬血细胞综合征患者为研究对象,采用单纯化疗(对照组)12例,血浆置换联合化疗(实验组)12例,观察其临床疗效及副作用。结果:对照组5例为临床有效,1例获临床缓解,3例疾病活动,3例为疾病再活动,有效率为50%;实验组7例为临床有效,3例获临床缓解,1例为疾病活动,1例为疾病再活动,有效率为83.3%;两组比较,差异有统计学意义(P<0.05)。结论:血浆置换联合HLH化疗对噬血细胞综合征治疗疗效确切。     

Impact of Guidelines for Antihypertensive Treatment on Clinical Practice

Many Guidelines and Consensus Statements were published in 1993 and 1994. The pressure to produce these guidelines comes from clinicians faced with rapid change, from a wish to provide an independent authoritative view rather than rely on commercial promotion of particular treatments, and from governments seeking assistance with the allocation of scarce resources.

Evaluation of the impact that guidelines exert on clinical practice is notoriously difficult, but has been attempted using the self-report questionnaire, or the more reliable but expensive analysis of actual practice data, before and after publication of the guidelines.     

Thrombotic microangiopathic hemolytic anemia in systemic lupus erythematosus associated with antiphospholipid antibodies: usefulness of monitoring coagulation–fibrinolysis markers

Abstract

We report on a 24-year-old woman with systemic lupus erythematosus and lupus anticoagulant who developed chronic thrombotic microangiopathic hemolytic anemia. The patient responded well to a combination of plasma exchange and anticoagulant therapy. Changes in the molecular markers for coagulation and fibrinolysis corresponded with the disease activity. We suggest that thrombotic microangiopathic hemolytic anemia should be suspected when anemia and thrombocytopenia of unknown etiologies occur in systemic lupus erythematosus. In such cases, the evaluation of molecular markers for coagulation and fibrinolysis might be helpful both for diagnosis and for assessing the response to therapy.